Deirdre Cohen

Regulation of Pancreatic Oncogenesis by RIP1 Kinase

National Cancer Institute · R01

PI · $381.4K · New York University School of Medicine

Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer

Principal investigator · Recruiting · Phase 2

Icahn School of Medicine at Mount Sinai

Study of Nivolumab, Cabiralizumab, and Stereotactic Body Radiotherapy (SBRT) for Locally Advanced Unresectable Pancreatic Cancer

Principal investigator · Terminated · Phase 2

NYU Langone Health

Study of Irinotecan and AZD1775, a Selective Wee 1 Inhibitor, in RAS or BRAF Mutated, Second-line Metastatic Colorectal Cancer

Principal investigator · Completed · Phase 1

NYU Langone Health

Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer

Principal investigator · Completed · Phase 2

National Cancer Institute (NCI)